This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (123)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Prognosis/ Outcomes  • Cardiac Diagnostic Tests  • Alert me on articles by topic  Social Bookmarking   What's this?

Peter M. Okin, MD; Richard B. Devereux, MD; Sverker Jern, MD; Sverre E. Kjeldsen, MD, PhD; Stevo Julius, MD, ScD; Markku S. Nieminen, MD, PhD; Steven Snapinn, PhD; Katherine E. Harris, DrPH; Peter Aurup, MD; Jonathan M. Edelman, MD; Hans Wedel, PhD; Lars H. Lindholm, MD, PhD; Björn Dahlöf, MD, PhD; for the LIFE Study Investigators

JAMA. 2004;292:2343-2349.

Context  Electrocardiographic left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular (CV) morbidity and mortality. However, the predictive value of changes in the magnitude of electrocardiographic LVH criteria during antihypertensive therapy remains unclear.

Objective  To test the hypothesis that lesser severity of electrocardiographic LVH during antihypertensive treatment is associated with decreased CV morbidity and mortality, independent of blood pressure levels and reduction and treatment modality.

Design, Setting, and Participants  Double-blind, randomized, parallel-group study conducted in 1995-2001 among 9193 men and women with hypertension aged 55 through 80 years (mean, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage criteria and enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study.

Interventions  Losartan- or atenolol-based treatment regimens, with follow-up assessments for at least 4 (mean, 4.8 [SD, 0.9]) years.

Main Outcome Measure  Composite end point of CV death, myocardial infarction (MI), or stroke in relation to severity of electrocardiographic LVH determined at baseline and on subsequent electrocardiograms obtained at 1 or more annual revisits.

Results  Cardiovascular death, nonfatal MI, or stroke occurred in 1096 patients (11.9%). In Cox regression models controlling for treatment type, baseline Framingham risk score, baseline and in-treatment blood pressure, and severity of baseline electrocardiographic LVH by Cornell product and Sokolow-Lyon voltage, less-severe in-treatment LVH by Cornell product and Sokolow-Lyon voltage were associated with 14% and 17% lower rates, respectively, of the composite CV end point (adjusted hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.82-0.90; P<.001 for every 1050-mm x ms [1-SD] decrease in Cornell product; and HR, 0.83; 95% CI, 0.78-0.88; P<.001 for every 10.5-mm [1-SD] decrease in Sokolow-Lyon voltage). In parallel analyses, lower Cornell product and Sokolow-Lyon voltage were each independently associated with lower risks of CV mortality (HR, 0.78; 95% CI, 0.73-0.83; P<.001; and HR, 0.80; 95% CI, 0.73-0.87; P<.001, respectively), MI (HR, 0.90; 95% CI, 0.82-0.98; P=.01; and HR, 0.90; 95% CI, 0.81-1.00; P = .04), and stroke (HR, 0.90; 95% CI, 0.84-0.96; P=.002; and HR, 0.81; 95% CI, 0.75-0.89; P<.001).

Conclusions  Less-severe electrocardiographic LVH by Cornell product and Sokolow-Lyon voltage criteria during antihypertensive therapy is associated with lower likelihoods of CV morbidity and mortality, independent of blood pressure lowering and treatment modality in persons with essential hypertension. Antihypertensive therapy targeted at regression or prevention of electrocardiographic LVH may improve prognosis.

Author Affiliations: Department of Medicine, Division of Cardiology, Cornell University Medical Center, New York, NY (Drs Okin and Devereux); Sahlgrenska University Hospital/Östra, Göteborg, Sweden (Drs Jern and Dahlöf); Ullevål University Hospital, Oslo, Norway (Dr Kjeldsen); University of Michigan Medical Center, Ann Arbor (Dr Julius); Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (Dr Nieminen); Amgen Inc, Thousand Oaks, Calif (Dr Snapinn); Merck Research Laboratories, West Point, Pa (Drs Harris and Aurup); Merck & Co Inc, Whitehouse Station, NJ (Dr Edelman); Nordic School of Public Health, Göteborg, Sweden (Dr Wedel); and Umeå University, Umeå, Sweden (Dr Lindholm).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension
Richard B. Devereux, Kristian Wachtell, Eva Gerdts, Kurt Boman, Markku S. Nieminen, Vasilios Papademetriou, Jens Rokkedal, Katherine Harris, Peter Aurup, and Björn Dahlöf
JAMA. 2004;292(19):2350-2356.
ABSTRACT | FULL TEXT  

Left Ventricular Hypertrophy: The Next Treatable, Silent Killer?
Julius M. Gardin and Michael S. Lauer
JAMA. 2004;292(19):2396-2398.
EXTRACT | FULL TEXT  

Left Ventricular Hypertrophy
Janet M. Torpy, Tiffany J. Glass, and Richard M. Glass
JAMA. 2004;292(19):2430.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypertension and Diabetes: What are the pros to treating early surrogates?
Schmieder
Diabetes Care 2009;32:S294-S297.
FULL TEXT  

Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease
Verdecchia et al.
Circulation 2009;120:1380-1389.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension
Reichek et al.
Hypertension 2009;54:731-737.
ABSTRACT | FULL TEXT  

Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study
Barrios et al.
Journal of Renin-Angiotensin-Aldosterone System 2009;10:168-173.
ABSTRACT  

QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study
Morin et al.
Eur Heart J 2009;0:ehp321v1-ehp321.
ABSTRACT | FULL TEXT  

Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents?
Armario and de la Sierra
Ther Adv Cardiovasc Dis 2009;3:197-204.
ABSTRACT  

Hemodynamic and Cardiac Effects of Chronic Eprosartan and Moxonidine Therapy in Stroke-Prone Spontaneously Hypertensive Rats
Mukaddam-Daher et al.
Hypertension 2009;53:775-781.
ABSTRACT | FULL TEXT  

Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment: The Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE)
Okin et al.
Circulation 2009;119:1883-1891.
ABSTRACT | FULL TEXT  

Muscle ring finger 1 mediates cardiac atrophy in vivo
Willis et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;296:H997-H1006.
ABSTRACT | FULL TEXT  

Vascular Structure and Function Is Correlated to Cognitive Performance and White Matter Hyperintensities in Older Hypertensive Patients With Subjective Memory Complaints
Kearney-Schwartz et al.
Stroke 2009;40:1229-1236.
ABSTRACT | FULL TEXT  

Cardiac remodelling and dysfunction in children with obstructive sleep apnoea: a community based study
Chan et al.
Thorax 2009;64:233-239.
ABSTRACT | FULL TEXT  

Cornell Product Left Ventricular Hypertrophy in Electrocardiogram and the Risk of Stroke in a General Population
Ishikawa et al.
Hypertension 2009;53:28-34.
ABSTRACT | FULL TEXT  

The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study.
Bluemke et al.
J Am Coll Cardiol 2008;52:2148-2155.
ABSTRACT | FULL TEXT  

Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients: The LIFE Study
Okin et al.
Circ Arrhythm Electrophysiol 2008;1:337-343.
ABSTRACT | FULL TEXT  

Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)
Gerdts et al.
Eur J Echocardiogr 2008;9:809-815.
ABSTRACT | FULL TEXT  

Incidence and Prognostic Implication of Unrecognized Myocardial Scar Characterized by Cardiac Magnetic Resonance in Diabetic Patients Without Clinical Evidence of Myocardial Infarction
Kwong et al.
Circulation 2008;118:1011-1020.
ABSTRACT | FULL TEXT  

Gender Differences in the Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy
Agabiti-Rosei and Salvetti
Hypertension 2008;52:59-60.
FULL TEXT  

Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy
Okin et al.
Hypertension 2008;52:100-106.
ABSTRACT | FULL TEXT  

Gender Differences in Left Ventricular Hypertrophy Regression
Escobar and Barrios
Hypertension 2008;51:e58-e58.
FULL TEXT  

Response to Gender Differences in Left Ventricular Hypertrophy Regression
Os et al.
Hypertension 2008;51:e59-e59.
FULL TEXT  

Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group
Schocken et al.
Circulation 2008;117:2544-2565.
ABSTRACT | FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

Reversibility of Cardiac Abnormalities in Morbidly Obese Adolescents
Ippisch et al.
J Am Coll Cardiol 2008;51:1342-1348.
ABSTRACT | FULL TEXT  

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study
Os et al.
Hypertension 2008;51:1103-1108.
ABSTRACT | FULL TEXT  

Review: The role of noninvasive hemodynamic monitoring in the evaluation and treatment of hypertension
Ferrario et al.
Ther Adv Cardiovasc Dis 2007;1:113-118.
ABSTRACT  

Review: New approaches to the assessment of left ventricular hypertrophy
Agabiti-Rosei et al.
Ther Adv Cardiovasc Dis 2007;1:119-128.
ABSTRACT  

In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
Okin et al.
Hypertension 2007;50:984-990.
ABSTRACT | FULL TEXT  

Left Ventricular Hypertrophy Reversal and Prevention of Diabetes: Two Birds With One Stone?
Schillaci et al.
Hypertension 2007;50:851-853.
FULL TEXT  

Regression of Electrocardiographic Left Ventricular Hypertrophy Is Associated with Less Hospitalization for Heart Failure in Hypertensive Patients
Okin et al.
ANN INTERN MED 2007;147:311-319.
ABSTRACT | FULL TEXT  

Persistent ischaemic ECG abnormalities on repeated ECG examination have important prognostic value for cardiovascular disease beyond established risk factors: a population-based study in middle-aged men with up to 32 years of follow-up
Strom Moller et al.
Heart 2007;93:1104-1110.
ABSTRACT | FULL TEXT  

Hypertension in the Young: Preventing the Evolution of Disease Versus Prevention of Clinical Events
Williams
J Am Coll Cardiol 2007;50:840-842.
FULL TEXT  

Quantitative Measures of Electrocardiographic Left Ventricular Mass, Conduction, and Repolarization, and Long-Term Survival After Coronary Artery Bypass Grafting
Lauer et al.
Circulation 2007;116:888-893.
ABSTRACT | FULL TEXT  

Cardiovascular Protection Using Beta-Blockers: A Critical Review of the Evidence
Bangalore et al.
J Am Coll Cardiol 2007;50:563-572.
ABSTRACT | FULL TEXT  

Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study
Wachtell et al.
Circulation 2007;116:700-705.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Adiponectin Level and Left Ventricular Hypertrophy in Japanese Men
Mitsuhashi et al.
Hypertension 2007;49:1448-1454.
ABSTRACT | FULL TEXT  

Blood Pressure and Estimated Risk of Stroke in the Elderly Population of Spain: The PREV-ICTUS Study
Redon et al.
Stroke 2007;38:1167-1173.
ABSTRACT | FULL TEXT  

Corin I555(P568) Allele Is Associated With Enhanced Cardiac Hypertrophic Response to Increased Systemic Afterload
Rame et al.
Hypertension 2007;49:857-864.
ABSTRACT | FULL TEXT  

Differences in Blood Pressure Control and Stroke Mortality Across Spain: The Prevencion de Riesgo de Ictus (PREV-ICTUS) Study
Redon et al.
Hypertension 2007;49:799-805.
ABSTRACT | FULL TEXT  

Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence--Reply
Okin and Devereux
JAMA 2007;297:40-41.
FULL TEXT  

Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study
Barrios et al.
Journal of Renin-Angiotensin-Aldosterone System 2006;7:236-242.
ABSTRACT  

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Okin et al.
JAMA 2006;296:1242-1248.
ABSTRACT | FULL TEXT  

Hypertension and the Heart.
Mancia et al.
SEMIN CARDIOTHORAC VASC ANESTH 2006;10:198-202.
ABSTRACT  

Impact of Unrecognized Myocardial Scar Detected by Cardiac Magnetic Resonance Imaging on Event-Free Survival in Patients Presenting With Signs or Symptoms of Coronary Artery Disease
Kwong et al.
Circulation 2006;113:2733-2743.
ABSTRACT | FULL TEXT  

Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan
Circulation 2006;113:2335-2362.
FULL TEXT  

Electrocardiogram: Still the Cardiologist's Best Friend
Stern
Circulation 2006;113:e753-e756.
FULL TEXT  

Regulation of Cardiac Stress Signaling by Protein Kinase D1
Harrison et al.
Mol. Cell. Biol. 2006;26:3875-3888.
ABSTRACT | FULL TEXT  

Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study
Okin et al.
Circulation 2006;113:1588-1596.
ABSTRACT | FULL TEXT  

Combined QT Interval and Voltage Criteria Improve Left Ventricular Hypertrophy Detection in Resistant Hypertension
Salles et al.
Hypertension 2005;46:1207-1212.
ABSTRACT | FULL TEXT  

Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure
Rothermel et al.
Physiol. Genomics 2005;23:18-27.
ABSTRACT | FULL TEXT  

Does load-induced ventricular hypertrophy progress to systolic heart failure?
Berenji et al.
Am. J. Physiol. Heart Circ. Physiol. 2005;289:H8-H16.
ABSTRACT | FULL TEXT  

C-Reactive Protein and Electrocardiographic ST-Segment Depression Additively Predict Mortality: The Strong Heart Study
Okin et al.
J Am Coll Cardiol 2005;45:1787-1793.
ABSTRACT | FULL TEXT  

JournalScan
Malik
Heart 2005;91:271-272.
FULL TEXT  

Regression of LV Hypertrophy in Hypertensive Patients
Journal Watch Cardiology 2004;2004:1-1.
FULL TEXT  

Should LVH Regression Be a Goal of Antihypertensive Treatment?
JWatch General 2004;2004:1-1.
FULL TEXT  

Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension
Devereux et al.
JAMA 2004;292:2350-2356.
ABSTRACT | FULL TEXT  

Left Ventricular Hypertrophy: The Next Treatable, Silent Killer?
Gardin and Lauer
JAMA 2004;292:2396-2398.
FULL TEXT